Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Product Portfolio > Late Stage > Apaziquone

Apaziquone for Intravesical Instillation

Apaziquone Mechanism of action

Apaziquone Mechanism of Action

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Apaziquone is an investigational drug not yet approved by the FDA.

Apaziquone is a bio-reductive agent activated by reductase enzymes, such as DT-diaphorase, expressed by bladder tumor cells, to form cytotoxic alkylating agents.

Development Indications

  • For intravesical instillation post-transurethral resection of bladder tumors (post-TURBT) in patients with Non-Muscle Invasive Bladder Cancer (NMIBC)

Latest News on Apaziquone

  • Aug 14, 2017
    Spectrum Pharmaceuticals Announces Initiation of the Registrational Phase 3 Trial of Apaziquone in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
    (Click Here for Press Release)
  • Sep 14, 2016
    FDA Advisory Committee Votes that Apaziquone Has Not Shown Substantial Evidence of a Treatment Effect Over Placebo
    (Click Here for Press Release)
  • May 6, 2016
    Spectrum Pharmaceuticals Highlights an Oral Presentation on Apaziquone at the 2016 Annual Meeting of the American Urological Association Education and Research Inc. (AUA) in San Diego, CA
    (Click Here for Press Release)
  • Feb 19, 2016
    Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for EOquin® (apaziquone for intravesical instillation)
    (Click Here for Press Release)
  • Oct 26, 2015
    Spectrum Pharmaceuticals Initiates Apaziquone Pivotal Trial for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) Following SPA Agreement
    (Click Here for Press Release)
  • Aug 17, 2015
    Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Upcoming Apaziquone Phase 3 Trial in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
    (Click Here for Press Release)
  • Jan 31, 2013
    Spectrum Pharmaceuticals Acquires Rights for Apaziquone in the U.S., Europe and Other Territories from Allergan; Expects to File New Drug Application
    (Click Here for Press Release)
  • Apr 5, 2012
    Spectrum Pharmaceuticals Announces Results of Apaziquone Phase 3 Clinical Trials
    (Click Here for Press Release)